Thermo Fisher set to build $180m viral vector site

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/EasternLightCraft)
(Image: Getty/EasternLightCraft)

Related tags: Thermo fisher scientific, Viral vectors, Massachusetts

The site will be responsible for commercial manufacturing and will double the company’s viral vector capacity.

Earlier this year in March, Thermo Fisher Scientific announced that it would invest $475m (€438m) into its biopharma business​, with a focus on providing services for the development of cell and gene therapies.

Last week, the company revealed that a significant chunk, $180m, would be apportioned to the creation of a commercial manufacturing site for viral vectors.

The site will be built in Massachusetts, US, and will cover 290,000-square-feet, with projections for the work to be completed in 2022.

The Plainville site will create in excess of 200 jobs and will support the development and manufacture of gene therapies and vaccines, the company stated.

In addition to the doubling the company’s capacity to produce viral vectors, Michel Lagarde, EVP of Thermo Fisher, noted that the project is part of its aim to ensure that customers do not need to work with other contract development and manufacturing organizations (CDMOs), as pat of its ‘start here, stay here’ strategy.

He added that the growing pipeline of cell and gene therapies has highlight the need customers have for access to ‘surge capacity’, with capacity bottlenecks​ being a growing headache for companies trying to develop such therapies.

The new site will be comprised of laboratory and production suites, with warehousing and office space also on-site.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more